Has Robin Rye received payments from drug or device companies?

Yes. Drug and device makers reported $10,912 in general payments to Robin Rye across 550 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Robin Rye did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Robin Rye come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Robin Rye

Nurse Practitioner · Whiteville, NCNPI 1639134059

Payments from drug & device makers

$10,912in general payments, 2019–2025

Across 550 payments — averaging $19.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AstraZeneca$2K
Novo Nordisk$1K
Bayer$1K
AbbVie$1K
Amgen$990
Astellas Pharma US Inc$599
plus $4K from 37 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AstraZeneca	53	$1,763
Novo Nordisk	75	$1,269
Bayer	67	$1,060
AbbVie	75	$1,052
Amgen(2 entities)	68	$990
Astellas Pharma US Inc	18	$599
Bausch Health US, LLC	31	$553
Lilly USA, LLC	29	$550
Novartis	20	$328
Esperion Therapeutics, Inc.	10	$314
Phathom Pharmaceuticals, Inc.	6	$282
Johnson & Johnson	2	$250
Ironwood Pharmaceuticals, Inc	10	$224
Takeda Pharmaceuticals U.S.A., Inc.	13	$219
Paratek Pharmaceuticals, Inc.	1	$125
Ardelyx, Inc.	6	$112
Amarin Pharma, Inc.	7	$105
Revance Therapeutics, Inc.	1	$97
Pfizer	6	$95
GSK	7	$93
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	6	$87
Exact Sciences	5	$77
Merz North America, Inc.	1	$72
Abbott	4	$71
Averitas Pharma Inc.	2	$65
Axsome Therapeutics, Inc.	3	$57
Merck	3	$54
Azurity Pharmaceuticals, Inc.	2	$38
Boehringer Ingelheim	2	$38
Tris Pharma Inc	2	$37
Corium, LLC	2	$31
Biohaven Pharmaceutical Holding Company Ltd.	2	$29
Insulet Corporation	1	$22
Endo USA, Inc.	1	$22
Viatris Specialty LLC	1	$18
Supernus Pharmaceuticals, Inc.	1	$17
Sunovion Pharmaceuticals Inc.	1	$15
Exeltis, USA Inc.	1	$15
Nabriva Therapeutics, PLC	1	$14
Intra-sana Laboratories	1	$14
Forte Bio-pharma LLC	1	$13
Arbor Pharmaceuticals, Inc.	1	$13
Teva Pharmaceuticals USA, Inc.	1	$12

How this compares

$10,912 in reported general payments places this provider in the 95th percentile of 4,393 nurse practitioner providers in North Carolina.

See all nurse practitioner providers in North Carolina →

Medicare billing

Part B allowed, 2024

$64,743

Medicare patients

Services billed

6,936

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other nurse practitioner in Whiteville

Sandrivette JohnsonRaleigh$573K
Skyler RogersPinehurst$174K
Jamie DinerDurham$170K
Ayeshia WrightMocksville$145K
Deborah AllenDurham$112K
Jeanann VawterGastonia$97K
Terra KampJacksonville$72K
Mary DilorenzoCharlotte$71K
Olivia OgburnWinston Salem$70K
Bridget ArchambaultDurham$57K

See the full list for North Carolina →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →